会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • IDENTIFICATION OF MODULATORS OF GPR31 ACTIVITY
    • GPR31活性调节剂的鉴定
    • WO0161360A3
    • 2002-03-28
    • PCT/GB0100693
    • 2001-02-19
    • GLAXO GROUP LTDWISE ALAN
    • WISE ALAN
    • G01N33/566C07K14/72A61P3/04A61P3/06A61P3/10
    • G01N33/566G01N2333/726G01N2500/00
    • The present invention provides a method for identification of an agent that modulates activity of G-protein coupled receptor 31 (GPR 31). The method comprises: (i) contacting a test agent with GPR 31 or a variant thereof which is capable of coupling to a G-protein; and (ii) monitoring for GPR 31 activity in the presence of a G-protein; thereby determining whether the test agent modulates GPR 31 activity. The invention also provides activators of GPR 31, inhibitors of lipolysis and GPR 31 polynucleotides which can be used in the treatment of dyslipidaemia, coronary heart disease, atheroscloresis, thrombosis or obesity, angina, chronic renal failure, peripheral vascular disease, stroke, type I diabetes or metabolic syndrome (syndrome X).
    • 本发明提供了一种鉴定调节G蛋白偶联受体31(GPR 31)活性的试剂的方法。 该方法包括:(i)使测试试剂与GPR31或其能够与G蛋白偶联的变体接触; 和(ii)在G蛋白存在下监测GPR 31活性; 从而确定测试剂是否调节GPR 31活性。 本发明还提供了可用于治疗血脂异常,冠心病,动脉粥样硬化,血栓形成或肥胖,心绞痛,慢性肾功能衰竭,外周血管疾病,中风,I型的GPR31激动剂,脂解作用抑制剂和GPR 31多核苷酸 糖尿病或代谢综合症(X综合症)。
    • 5. 发明申请
    • NOVEL ASSAY
    • 新的测定
    • WO0161359A2
    • 2001-08-23
    • PCT/GB0100684
    • 2001-02-19
    • GLAXO GROUP LTDWISE ALANBROWN ANDREW JAMES
    • WISE ALANBROWN ANDREW JAMES
    • A61P3/04A61P3/06A61P3/10G01N33/566G01N33/68
    • G01N33/566G01N2333/726G01N2500/10
    • This invention relates to a method for identification of an agent that modulates activity of G-protein coupled receptor 41 (GPR 41), or G-protein coupled receptor 42 (GPR 42) which method comprises: (i) contacting a test agent with GPR 41, GPR42 or a variant of either thereof which is capable of coupling to a G-protein; and (ii) monitoring for GPR 41 or GPR 42 activity in the presence of a G-protein; thereby determining whether the test agent modulates GPR 41 or GPR 42 activity. An agent identifiable by this method is provided for use in the treatment of dyslipidaemia, coronary heart disease, atheroselerosis, thrombosis or obesity, angina, chronic renal failure, peripheral vascular disease, stroke, type II diabetes or metabolic syndrome (syndrome X).
    • 本发明涉及一种用于鉴定调节G蛋白偶联受体41(GPR 41)或G蛋白偶联受体42(GPR 42)的活性的试剂的方法,该方法包括:(i)将测试试剂与GPR 41,GPR42或其能够与G蛋白偶联的任一种的变体; 和(ii)在G蛋白存在下监测GPR 41或GPR 42活性; 从而确定测试剂是否调节GPR 41或GPR 42活性。 通过该方法识别的药剂可用于治疗血脂异常,冠心病,动脉粥样硬化,血栓形成或肥胖,心绞痛,慢性肾功能衰竭,外周血管疾病,中风,II型糖尿病或代谢综合征(综合征X)。